Senators question Allergan CEO on tribe patent deal

A group of five senators said the deal was a "blatant attempt to further Allergan's market monopoly" on its $1.5 billion eye drug, Restasis.

Trump's abandoned promise to bring down drug prices, explained - Vox

Irish America August / September 2019 by Irish America Magazine - Issuu

Prescription Drug Costs

Supreme Court case could deal a blow to Mohawk tribe's patent plan

A handful of Allergan's top shareholders want to bring back the old CEO as chairman

Single-Payer Healthcare Takes a Big Step Forward

CQ Researcher - Prescription Drug Costs

Speaker Bios Do Not Delete - Foundry Events

Senators blast Allergan's tribal deal, social contract as 'hypocrisy

Allergan plc

All eyes on Saint Regis Mohawk Tribe in contentious patent case